» Articles » PMID: 3418641

Depression in Rheumatoid Arthritis

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 1988 Jun 1
PMID 3418641
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Operationalized diagnostic criteria for depression were used to assess 137 (76% male, 24% female) patients with rheumatoid arthritis (RA). Forty-two percent met criteria for some form of depression. Discriminant function analysis revealed a significant relationship between the presence or history of depression and higher levels of pain, but not between current depression and common indicators of RA activity or severity. These results suggest that depression is a frequent disorder among persons with RA. The importance of patient appraisal of disease and assessment of repeated depressive episodes is discussed. Attention to specific interventions for depression in conjunction with the treatment of the RA is suggested.

Citing Articles

Diagnosis of Mental Disorders Complicated by Rheumatoid Arthritis: A Study of the Validity of a Questionnaire Method and Diagnosis by the Psychiatrist.

Yusuke M, Hiroi T, Yuko M Eur J Rheumatol. 2024; 11(4):405-409.

PMID: 39651874 PMC: 11639603. DOI: 10.5152/eurjrheum.2024.24014.


An integrated approach to the treatment of Rheumatic diseases: the role of psychological interventions.

Bekarissova S, Bekarisov O, Bekaryssova D Rheumatol Int. 2024; 44(12):2727-2735.

PMID: 39400563 DOI: 10.1007/s00296-024-05728-9.


Antidepressant in the Treatment of Chronic Pain: A Case Report of Adult-Onset Still's Disease.

Jain A, Bodicherla K, Vanaparthy R Cureus. 2022; 13(12):e20180.

PMID: 35004004 PMC: 8723779. DOI: 10.7759/cureus.20180.


Association between health behaviours and depression: findings from a national cross-sectional study in South Korea.

Jang B, Lee H, Joo J, Park E, Jang S BMC Psychiatry. 2020; 20(1):238.

PMID: 32408865 PMC: 7227033. DOI: 10.1186/s12888-020-02628-7.


Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.

Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A Arthritis Res Ther. 2019; 21(1):263.

PMID: 31791386 PMC: 6889334. DOI: 10.1186/s13075-019-2059-8.